WCI

RI Related News

비회원이 작성한 글입니다!

글작성시 입력했던 비밀번호를 입력해주세요.

List Next Prev
게시글 내용
Clovis Oncology Highlights FAP-2286 Preclinical Data Presented At The Targeted Radiopharmaceuticals Summit
2022/01/06

Clovis Oncology, Inc. released the presentation by Andrew D. Simmons, Ph.D., Clovis’ Senior Vice President,at the 3rd Targeted Radiopharmaceuticals Summit held virtually December 7-9, 2021. Dr. Simmons’ presentation, titled “Innovations in Peptide Targeted Radionuclide Therapies (PTRT) to Target Fibroblast Activation Protein (FAP) in Solid Tumors”, reviews the Company’s preclinical data and describes the Phase 1/2 study currently enrolling for its targeted radiotherapy candidate FAP-2286, the first PTRT and imaging agent targeting FAP to enter clinical development and the lead candidate in Clovis Oncology’s targeted radionuclide therapy (TRT) development program.

 

To read more please visit:

Clovis Oncology Highlights FAP-2286 Preclinical Data Presented At The Targeted Radiopharmaceuticals Summit

Source: CLOVIS ONCOLOGY